IN8bio, Inc.NASDAQ: INAB

IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

· Issued by IN8bio, Inc. via GlobeNewswire

Summary by 6ix AI

IN8bio, a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies and T cell engagers for cancer and autoimmune diseases, said CEO and Co-Founder William Ho will take part in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on Monday, September 14, 2026.

Key details

  • The fireside chat is at 10:00 a.m. ET in Kennedy II, 4th Floor, Lotte New York Palace Hotel, New York City.
  • Mr. Ho and members of the IN8bio management team will hold one-on-one meetings with investors throughout the conference.
  • A live webcast will be available through the Investors section of IN8bio's website, with a replay available after the event.

6ix AI wrote this summary from the release below and checked it against the release.

NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and Co-Founder, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference, on Monday, September 14, 2026, in New York.

Mr. Ho and members of the IN8bio management team will host one-on-one meetings with investors throughout the conference.

H.C. Wainwright 28th Annual Global Investment Conference
Date: Monday, September 14, 2026
Time: 10:00 a.m. ET
Format: Fireside Chat
Presenter: William Ho, Chief Executive Officer and Co-Founder
Location: Kennedy II, 4th Floor, Lotte New York Palace Hotel, New York City
Webcast: Webcast Link

A live webcast of the presentation will be available through the Investors section of IN8bio's website. A replay will be available following the event.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's pipeline is anchored by INB-600, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also advancing INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit www.IN8bio.com.

Investors and Corporate Contact:

IN8bio, Inc.
Patrick McCall
646.933.5603
[email protected]

Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
[email protected]

IN8bio, Inc. on 6ix

Story so far

Earlier from IN8bio

Later from IN8bio

All IN8bio news releases